Trial Profile
Phase I/II Study to Evaluate the Safety, Efficacy, and Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Aug 2023
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Panitumumab (Primary) ; Telaglenastat (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Calithera Biosciences
- 01 Jul 2023 Results (n=17) from phase 2 part, presented at the 25th World Congress on Gastrointestinal Cancer
- 06 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.